Katelyn Vignola
Primary Care · Orlando, FLNPI 1336616044
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,572 of the $7,099 with a category attached, or 78.5%. 30 manufacturers reported payments, led by Gilead at 39.4% of the total. Reporting peaked in 2024 at $2,968 and has fallen 94.1% since, to $174 in 2025. Among primary care clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 221 payments — averaging $32.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$3K
- Viiv Healthcare Company$842
- AbbVie$807
- Amgen$643
- Merck$514
- Theratechnologies Inc.$238
- plus $1K from 24 others
What the payments were for
- Consulting fees$1,33019%
- Travel & lodging$210%
- Food & beverage$5,57278%
- Education$1762%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 52 | $2,794 |
| Viiv Healthcare Company | 34 | $842 |
| AbbVie | 29 | $807 |
| Amgen | 19 | $643 |
| Merck | 24 | $514 |
| Theratechnologies Inc. | 9 | $238 |
| Johnson & Johnson(2 entities) | 11 | $203 |
| Biohaven Pharmaceuticals, Inc. | 5 | $186 |
| GSK | 3 | $158 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $100 |
| Novo Nordisk | 5 | $90 |
| Janssen Scientific Affairs, LLC | 3 | $74 |
| AstraZeneca | 5 | $67 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $46 |
| Hologic Sales And Service, LLC | 2 | $40 |
| Lilly USA, LLC | 2 | $35 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $27 |
| Boehringer Ingelheim | 1 | $27 |
| EMD Serono, Inc. | 1 | $27 |
| Abbott | 1 | $25 |
| Alnylam Pharmaceuticals Inc. | 1 | $24 |
| Alkermes, Inc. | 1 | $24 |
| Sanofi-aventis U.S. LLC | 1 | $20 |
| Daiichi Sankyo Inc. | 1 | $17 |
| Jazz Pharmaceuticals Inc. | 1 | $15 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $14 |
| Currax Pharmaceuticals LLC | 1 | $14 |
| Dexcom, Inc. | 1 | $11 |
| Indivior Inc. | 1 | $11 |
| Clarus Therapeutics Inc. | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$131
- TRELEGY ELLIPTA$122
- AIMOVIG$122
- Otezla$122
- Descovy$121
- QULIPTA$116
- DOVATO$112
- VRAYLAR$102
How this compares
$7,099 in reported general payments places this provider in the 95th percentile of 725 primary care providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 27 | $126,313 |
| DescovyEmtricitabine/Tenofov Alafenam | 31 | $64,462 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 14 | $52,393 |
| PifeltroDoravirine | 13 | $21,516 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 11 | $5,136 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $4,746 |
| Ultra-Fine Nano Pen NeedlePen Needle, Diabetic | 12 | $745 |
| Gabapentin | 13 | $270 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 16 | $249 |
| Pantoprazole Sodium | 14 | $167 |
| Vitamin D2Ergocalciferol (Vitamin D2) | 15 | $54 |
| Rosuvastatin Calcium | 20 | $50 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadDescovy, Biktarvy | $2,794 | $116,85445 claims |
| MerckPifeltro | $514 | $21,51613 claims |
| GSKAnoro Ellipta | $158 | $5,13611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 725 primary care providers in Florida.
Other primary care in Orlando
- Paul ChanOrlando$447K
- Shaquana BrooksOrlando$3K
- Jenny WestPensacola$80K
- Railet RodriguezAltamonte Springs$14K
- Kevin HanawayFort Lauderdale$12K
- Kelly ChewningAlachua$11K
- Yolanda PalmeroSaint Cloud$11K
- Erica ClarkCitrus Springs$11K
- Michelle SelvaggiLakewood Ranch$10K
- Kristen DeasonTallahassee$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.